Aignostics

Aignostics is an international company focused on advancing precision medicine and computational pathology through artificial intelligence (AI). Founded in 2018 in Berlin, the company spun out in 2020 and now has offices in Berlin and New York. Aignostics aims to transform drug development and improve patient outcomes by extracting insights from complex biomedical data. The company offers a variety of custom services for image and data analysis throughout the biopharma value chain. These services include target and biomarker discovery, translational research, and digital diagnostics. Aignostics also provides products for precision medicine, such as pathology foundation models and the Aignostics Atlas Product Series, which includes applications for tumor microenvironment profiling. Aignostics collaborates with leading academic institutions, including a partnership with Mayo Clinic, to develop advanced pathology models. The company has raised over $55 million in funding, supporting its mission to enhance drug development and diagnostics through AI-driven solutions.

Information Technology & Services Berlin, Germany ~4 employees Private · Series B

Work at Aignostics in HR or recruiting? Claim this page

Employees
4
0% in the 3 months to Jun 2025
Revenue / employee
$375K
Revenue ~$1.5M
Total funding
$48M
Last round Series B, Oct 2024
12-month attrition
25%
Tech: 0%
H1B sponsor
NA

Headcount trend

Aignostics went from 2 employees in Jul 2023 to 4 in Jun 2025.

Headcount data through Jun 2025

Funding rounds

Total funding$48M
Funding rounds3
Investors9

Org structure

Headcount by department

Sales2
Marketing1
Engineering1

Aignostics FAQ

How many employees does Aignostics have?

Aignostics has about 4 employees, unchanged over the 3 months to Jun 2025.

What is Aignostics's revenue per employee?

Aignostics makes about $375K in revenue per employee, based on $1.5M annual revenue and 4 employees.

How much funding has Aignostics raised?

Aignostics has raised $47.98M in total funding; its latest round was Series B in Oct 2024.

Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.